key: cord-0944790-k3eukxen authors: Hawman, David W.; Meade-White, Kimberly; Clancy, Chad; Archer, Jacob; Hinkley, Troy; Leventhal, Shanna S.; Rao, Deepashri; Stamper, Allie; Lewis, Matthew; Rosenke, Rebecca; Krieger, Kyle; Randall, Samantha; Khandhar, Amit P.; Hao, Linhue; Hsiang, Tien-Ying; Greninger, Alexander L.; Gale, Michael; Berglund, Peter; Fuller, Deborah Heydenburg; Rosenke, Kyle; Feldmann, Heinz; Erasmus, Jesse H. title: Replicating RNA platform enables rapid response to the SARS-CoV-2 Omicron variant and elicits enhanced protection in naïve hamsters compared to ancestral vaccine date: 2022-02-02 journal: bioRxiv DOI: 10.1101/2022.01.31.478520 sha: 28ba19932bd78d33bfb60b9ae47334502a679a05 doc_id: 944790 cord_uid: k3eukxen In late 2021, the SARS-CoV-2 Omicron (B.1.1.529) variant of concern (VoC) was reported with many mutations in the viral spike protein that were predicted to enhance transmissibility and allow viral escape of neutralizing antibodies. Within weeks of the first report of B.1.1.529, this VoC has rapidly spread throughout the world, replacing previously circulating strains of SARS-CoV-2 and leading to a resurgence in COVID-19 cases even in populations with high levels of vaccine- and infection-induced immunity. Initial studies have shown that B.1.1.529 is less sensitive to protective antibody conferred by previous infections and vaccines developed against earlier lineages of SARS-CoV-2. The ability of B.1.1.529 to spread even among vaccinated populations has led to a global public health demand for updated vaccines that can confer protection against B.1.1.529. We report here the rapid development of a replicating RNA vaccine expressing the B.1.1.529 spike and show that this B.1.1.529-targeted vaccine is immunogenic in mice and hamsters. Interestingly, we found that mice previously immunized with A.1-specific vaccines failed to elevate neutralizing antibody titers against B.1.1.529 following B.1.1.529-targeted boosting, suggesting pre-existing immunity may impact the efficacy of B.1.1.529-targeted boosters. Furthermore, we found that our B.1.1.529-targeted vaccine provides superior protection compared to the ancestral A.1-targeted vaccine in hamsters challenged with the B.1.1.529 VoC after a single dose of each vaccine. One Sentence Summary Rapidly developed RNA vaccine protects against SARS-CoV-2 Omicron variant Since emerging in late 2019 in China, severe acute respiratory disease -coronavirus 2 (SARS-CoV-2) has caused hundreds of millions of infections and the associated disease, COVID-19, resulting in millions of deaths. As of early 2022, the virus continues to circulate throughout the world. To address the pandemic, multiple vaccines were rapidly developed and early reports showed high levels of protection against symptomatic infection, severe disease and hospitalization (1). However, continued viral evolution has given rise to variants of concern (VoC) with abilities to evade vaccine-or infection-induced immunity and increase transmissibility (2) (3) (4) (5) . However, the recent emergence of the B.1.1.529 (Omicron) VoC in late 2021 (6) has resulted in an unprecedented resurgence of COVID-19 cases with many countries reporting record case numbers. Remarkably, in the United States, the B.1.1.529 VoC represented less than 1% of cases in early December 2021 but by mid-January 2022, was responsible for >99% of cases (7) . The remarkable replacement of previously circulating SARS-CoV-2 strains by B.1.1.529 is likely due to 1) the ability of the B.1.1.529 to evade either vaccine-or infection-induced immunity (8) (9) (10) (11) enabling B.1.1.529 to spread among previously resistant populations, and 2) increased transmissibility as many of the described mutations have been previously implicated in enhancing the receptor binding domain's affinity for the ACE2 receptor (12, 13) with B.1.1.529 also appearing to replicate efficiently in the upper respiratory tract promoting efficient transmission in rodent models of infection (14) . The emergence of B.1.1.529 and its resistance to previously acquired immunity has resulted in a public health demand for updated vaccines that can limit infection and transmission of the B.1.1.529 VoC to address the ongoing public health threat posed by SARS-CoV-2. Genetic immunizationbased vaccine technologies, including those based on mRNA modalities, provide the ability to rapidly respond to such changes in the virus and the currently approved mRNA vaccines for COVID-19 are in the process of being updated (15) . Previously, we reported on the development of a cationic nanocarrier, Lipid InOrganic Nanoparticle (LION), for delivery of a replicating RNA (repRNA) encoding the ancestral Spike of SARS-CoV-2 (16) as well as those of the B.1.1.7 and B.1.351 lineage viruses (17) . Investigatory COVID-19 vaccine products based on the LION/repRNA platform are currently under evaluation in an ongoing phase II/III trial in India, under the drug product designation HDT/Gennova COVID-19 (HGC019, clinical trial identifier CTRI/2021/09/036379), and in ongoing phase I trials in South Korea under the name QTP104, as well as in Brazil and the US under the name HDT-301. In contrast to lipid nanoparticle (LNP)-based approaches for RNA delivery, cationic nanocarriers provide a distinct stability and independent manufacturing advantage that enables their stockpiling for rapid response to emerging diseases, including variants of SARS-CoV-2. Upon manufacture of updated repRNAs, the two components are simply combined and mixed by inversion, prior to loading of syringes for intramuscular injection. We report here the rapid development of a B.1.1.529-targeted repRNA and demonstrate that this vaccine is immunogenic and confers improved protection against B.1.1.529 infection in a hamster model compared to the ancestral A.1-specific vaccine, indicating that B.1.1.529-targeted vaccines are likely needed for optimal protection against B.1.1.529 infection. Importantly however, we also evaluated the immunogenicity of a B.1.1.529targeted vaccine as a booster in A.1-pre-immune mice and found that pre-existing immunity could negatively impact VoC-targeted booster responses. Design and production of a B.1.1.529-targeted repRNA-CoV2S. Following the November 25 th , 2021, announcement of a new VoC, first discovered in South Africa and designated by the WHO as the Omicron variant, we initiated nonclinical activities to rapidly update our repRNA-CoV2S, including vaccine design, as well as in vitro and in vivo evaluations, to inform ongoing clinical studies of our COVID-19 vaccine (Fig. 1A) . We screened the sequences deposited on GISAID available at that time for complete coverage of the spike (S) open reading frame (ORF) andselected EPI_ISL_6699769, deposited by de Oliveira et al (6) , to design an updated S ORF for insertion into our previously described repRNA-CoV2S (16, 17) (Fig. 1B) . Following the rapid synthesis of three overlapping tiles, we cloned and sequenced-verified B.1.1.529-repRNA-CoV2S prior to production of RNA for in vitro qualification using an in vitro potency assay. A half-maximal effective concentration (EC50) of 13.3 ng/well was measured ( Fig. 1C) , an expected potency within the range of previous repRNA-CoV2 drug substances (17) . Vaccination of pre-immune or naïve animals elicits differential antibody responses. Due to the prevalence of SARS-CoV2 immunity in the global population and the current need to boost pre-immune individuals we initiated a single or two-dose booster study in three groups of pre-immune mice. These animals had previously received 1µg doses, spaced 28 days apart, of either a prime/boost A.1-repRNA- In these studies, nAb responses against heterologous virus were not improved following a heterologous booster compared to those who received another A.1 homologous booster (27, 28) . These data suggest that boosting immune individuals with vaccines specific for an emergent VoC may fail to confer robust immunity against the VoC or could require more than one booster. The mechanisms underlying these findings are not clear. However, like the animals in the study reported here, the human subjects in the cited studies had low to moderate levels of circulating A.1-specific antibody at the time of the boost that may have interfered with interactions between mRNA-produced antigen and B cells or other compartments of the immune system. Alternatively, pre-existing cross-reactive memory B cells could be preferentially recalled, rather than mounting de novo responses via naïve B-cell interactions, as is hypothesized to occur following vaccination in influenza pre-immune individuals (29) . In contrast, studies investigating the immunogenicity of a second A.1 booster or 3 rd dose in previously vaccinated individuals reported significant increases in serum neutralization activity against not only A.1 but also heterologous B.1.1.529 as well as other VoCs (21, 22, (30) (31) (32) . This effect may be explained by the continued boosting of A.1-specific nAb titers that raises the overall antibody levels and expands rarer cross-neutralizing and/or lower-affinity antibodies, to protective levels. Indeed, a recent study of cases in 10 states as part of the VISION Network, showed that receipt of a third vaccine dose was highly effective at preventing COVID-19-associated hospitalizations during both Delta and Omicronpredominant periods (33) However, as A.1-specific immunity wanes, B.1.1.529 immunity is likely to disappear first (28, 34) . Indeed, breakthrough cases in populations that received a 3 rd dose suggest that protection from B.1.1.529 infection after boosting with the current A.1 vaccines is incomplete (8, 35) , thus prompting the development of updated vaccines that match B.1.1.529. However, our data suggest pre-existing immunity may interfere with protective efficacy of updated vaccines. More data is urgently needed to further characterize and understand the impact of pre-existing immunity on updated vaccines. Lastly, the rapid pace at which B.1.1.529 replaced other circulating SARS-CoV-2 strains (7) (14, 18, 19) , we found little to no pathology in the lungs of infected hamsters. Cumulatively, our data shows that we were able to rapidly synthesize and test a B. A scheduled necropsy at day 4 PI was performed on all animals to harvest blood and tissues. Studies were performed once. Viral RNA quantification. Viral RNA from swabs was isolated using Qiamp RNA mini kit (Qiagen) and viral RNA was isolated from tissues using RNEasy mini kit (Qiagen) according to provided protocols. Viral RNA was quantified by one-step qRT-PCR using QuantiFast Probe PCR reagents (Qiagen) and primers and probes specific for the SARS-CoV2 sub-genomic E RNA as previously described (43). For both assays, cycling conditions were as follows: initial hold of 50°C for 10min, initial denaturation of 95°C for 5min, and 40 cycles of 95°C for 15sec followed by 60°C 30sec. SARS-CoV2 RNA standards with known copy number were prepared in house, diluted, and run alongside samples for quantification. The limit of detection was based on the standard curve and defined as the quantity of RNA that would give a Ct value of 40. Infectious virus titration. Infectious virus in swabs or tissues was quantified by tissue-culture infectious dose 50 assay (TCID50) on Vero cells. Tissues were weighed and homogenized in 1mL DMEM supplemented with 2% FBS and penicillin and streptomycin. Homogenate was clarified of large debris by centrifugation. Samples were then serially 10-fold diluted in DMEM 2% FBS and applied to wells beginning with the 1:10 dilution in triplicate. Cells were incubated for six days before cytopathic effect (CPE) was read. TCID50 was determined by the Reed and Muench method (44). The limit of detection was defined as at least two wells positive in the 1:10 dilution. Histopathology and Immunohistochemistry. At time of necropsy, lungs were dissected and insufflated with 10% neutral buffered formalin. The skull was sectioned and lungs and skull sections submerged in 10% neutral buffered formalin for a minimum of 7 days with 2 changes. Tissues were placed in cassettes and processed with a Sakura VIP-6 Tissue Tek, on a 12-hour automated schedule, using a graded series of ethanol, xylene, and ParaPlast Extra. Prior to staining, embedded tissues were sectioned at 5 µm and dried overnight at 42°C. Specific anti-CoV immunoreactivity was detected using Sino Biological Inc. SARS-CoV/SARS-CoV-2 N antibody (Sino Biological cat#40143-MM05) at a 1:1000 dilution. The secondary antibody was the Vector Laboratories ImPress VR anti-mouse IgG polymer (cat# MP-7422). The tissues were then processed for immunohistochemistry using the Discovery Ultra automated stainer (Ventana Medical Systems) with a ChromoMap DAB kit (Roche Tissue Diagnostics cat#760-159). Sections were scored by a certified pathologist who was blinded to study groups. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding The N501Y spike substitution enhances SARS-CoV-2 infection and transmission The SARS-CoV-2 B.1.1.529 Omicron virus causes attenuated infection and disease in mice and hamsters COVID-19 vaccine makers chase variant-ready vaccines An Alphavirus-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates SARS-CoV2 variant-specific replicating RNA vaccines protect from disease and pathology and reduce viral shedding following challenge with heterologous SARS-CoV2 variants of concern. bioRxiv : the preprint server for biology The omicron (B.1.1.529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters. bioRxiv : the preprint server for biology Convalescence from prototype SARS-CoV-2 protects Syrian hamsters from disease caused by the Omicron variant. bioRxiv : the preprint server for biology SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters Plasma Neutralization of the SARS-CoV-2 Omicron Variant mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa. medRxiv Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization The success of SARS-CoV-2 vaccines and challenges ahead Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination Original Antigenic Sin: How Original? How Sinful? Cold Spring Harb Perspect Med 11 Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera Mapping the antigenic diversification of SARS-CoV-2. medRxiv Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance -VISION Network, 10 States mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern Israeli study shows 4th shot of COVID-19 vaccine less effective on Omicron India's Biggest Cities See Covid-19 Cases Fall Sharply, Raising Hopes for Omicron Peak Omicron: South Africa says fourth wave peak has passed as it lifts curfew Covid-19: England prepares to ease plan B restrictions BioNTech says it could tweak Covid vaccine in 100 days if needed. The Guardian (newspaper) Omicron sub-variant BA.2 'under investigation' by UK health officials. Independent Simulation of the Clinical and Pathological Manifestations of Coronavirus Disease 2019 (COVID-19) in a Golden Syrian Hamster Model: Implications for Disease Pathogenesis and Transmissibility The titer of the P1 stock was measured by standard SARS-CoV-2 plaque assay as described An aliquot of the P1 stock was subject to RNA isolation and complete SARS-CoV-2 genome sequencing (RNAseq) using the Swift Biosciences' SARS-CoV-2 multiplex amplicon sequencing panel pangolin) from which we confirmed the isolated virus was the omicron variant. VeroE6-TMPRSS2 (JCRB1819, JCRB Cell Bank, NIBIOHN) cells were cultured at 37C in DMEM supplemented with 10% FBS, 100U/ml of penicillin-streptomycin, and 1mg/ml G418. Baby Hamster Kidney (BHK) cells (ATCC) were cultured at 37C in DMEM Tiles were then synthesized on the BioXP (CodexDNA) and combined with linearized repRNA plasmid backbone in a four-fragment Gibson assembly reaction followed by transformation of e. coli and selection of clones. Sanger sequence-verified plasmid was then scaled prior to linearization by NotI digestion in preparation for transcription and capping as described (16) . To prepare vaccines for in vitro and in vivo experiments, RNA was combined with HDT Bio's stockpiled cationic nanocarrier Briefly, serial dilutions of LION/repRNA were incubated on a monolayer of BHK cells in a 96-well plate. Twenty-four hours later, cell lysates were added to an ELISA plate coated with anti-SARS-CoV2 Spike (S1 domain) monoclonal antibody. Following a primary incubation and washes, a polyclonal anti-SARS-CoV2 Spike (full-length S) primary antibody was added. Following a secondary incubation and washes, a secondary horse radish peroxidase (HRP)-conjugated antibody was used to detect S-specific binding. Following a final incubation, HRP activity was assayed by TMB/HCL detection and absorbance measured by plate reader Two-fold serial dilutions of heat inactivated serum and 600 plaque-forming units (PFU)/ml solution of A.1, or B.1.1.559 viruses were mixed 1:1 in DMEM and incubated for 30 min at 37C. Serum/virus mixtures were added, along with virus only and mock controls, to Vero E6-TMPRSS2 cells (ATCC) in 12-well plates and incubated for 30 min at 37C. Following adsorption Plates were then incubated for 2 (A.1) or 3 (B.1.1.529) days at 37C. Following incubation, 10% formaldehyde (Sigma-Aldrich) in DPBS was added to cells and incubated for 30 minutes at room temperature. Plates were then stained with 1% crystal violet Plaques were enumerated and percent neutralization was calculated relative to the virus-only control Antigen-specific IgG responses were detected by ELISA using recombinant A.1 full-length spike, A.1 receptor binding domain (RBD), or B.1.1.529 RBD (Sino Biological). ELISA plates (Corning) were coated with 1 µg/ml antigen or with serial dilutions of purified Trachea Tracheitis NA 1 1 1 2 2 2 1 NA 1 2 0 1 NA NA 0 0 NA Squamous metaplasia NA 0 0 0 2 0 0 0 NA 0 1 0 0 NA NA 0 0 NA Lung Bronchiolitis 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Interstitial pneumonia 0 0 0 1 0 0 0 0 1 1 0 0 0 0 0 1 0 0 Cellular exudate 0 0 0 1 1 0 0 0 1 1 0 0 0 0 0 1 0 0 Perivasculitis 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 Immuno Trachea NA + --+ + + -NA + + + -NA NA - -NA Bronchiole Transitional 3 2 3 2 2 2 3 3 3 3 3 3 2 2 3 2 2 2 Ciliated 2 3 3 3 3 3 3 3 2 3 2 2 2 2 3 2 Severe + Present -Absent